An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Osteopenia
Interventions
DRUG

Placebo

Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.

DRUG

AMG 167

Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY